Pluristem Therapeutics CEO Zami Aberman's 2012 pay rises 14% to $1.5M
Pluristem Therapeutics reports 2012 executive compensation
By ExecPay News
Published: March 29, 2013
Pluristem Therapeutics reported fiscal year 2012 executive compensation information on March 29, 2013.
In 2012, two executives at Pluristem Therapeutics received on average a compensation package of $1.2M, a 14% increase compared to previous year.
Average pay of disclosed executives at Pluristem Therapeutics
Zami Aberman, Chief Executive Officer, received $1.5M in total, which increased by 14% compared to 2011. 60% of Aberman's compensation, or $900K, was in stock awards. Aberman also received $75K in non-equity incentive plan, $496K in salary, as well as $22K in other compensation.
Yaky Yanay, Chief Financial Officer, received a compensation package of $974K, which increased by 13% compared to previous year. 66% of the compensation package, or $643K, was in stock awards.
Pluristem Therapeutics' fiscal year ends on June 30.
Related executives
You may also like
Source: SEC filing on March 29, 2013.